# Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

> **NCT02802748** · EARLY_PHASE1 · COMPLETED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 60 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Oral Vinorelbine
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02802748
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802748, "Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02802748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*